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ABSTRACT The ectoenzyme CD39 suppresses thrombo-
sis and inflammation by suppressing ATP and ADP to
AMP. However, mechanisms of CD39 transcriptional
and post-translational regulation are not well known.
Here we show that CD39 levels are modulated by
inhibition of phosphodiesterase 3 (PDE3). RAW mac-
rophages and human umbilical vein endothelial cells
(HUVECs) were treated with the PDE3 inhibitors
cilostazol and milrinone, then analyzed using qRT-
PCR, immunoprecipitation/Western blot, immunoflu-
orescent staining, radio-thin-layer chromatography, a
malachite green assay, and ELISA. HUVECs expressed
elevated CD39 protein (2-fold [P<0.05] for cilostazol
and 2.5-fold [P<0.01] for milrinone), while macro-
phage CD39 mRNA and protein were both elevated
after PDE3 inhibition. HUVEC ATPase activity in-
creased by 25% with cilostazol and milrinone treatment
(P<0.05 and P<0.01, respectively), as did ADPase
activity (47% and 61%, P<0.001). There was also a
dose-dependent elevation of soluble CD39 after treat-
ment with 8-Br-cAMP, with maximal elevation of 60%
more CD39 present compared to controls (1 mM,
P<0.001). Protein harvested after 8-Br-cAMP treatment
showed that ubiquitination of CD39 was decreased by
43% compared to controls. A DMSO or PBS vehicle
control was included for each experiment based on
solubility of cilostazol, milrinone, and 8-Br-cAMP.
These results indicate that PDE3 inhibition regulates
endothelial CD39 at a post-translational level.—Baek,
A. E., Kanthi, Y., Sutton, N. R., Liao, H., Pinsky, D. J.
Regulation of ecto-apyrase CD39 (ENTPD1) expres-
sion by phosphodiesterase III (PDE3). FASEB J. 27,
4419–4428 (2013). www.fasebj.org
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The processes of thrombosis and inflammation con-
tribute significantly to the severity and progression of
numerous disease states, including stroke and athero-
sclerosis (1, 2). Extracellular purinergic signaling
through ATP and ADP has been shown to be a potent
trigger for inflammatory cell recruitment and throm-
bosis. Modulating this pathway is the plasmalemmal
ectonucleotidase, CD39/NTPDase1 (ectonucleoside tri-
phosphate diphosphohydrolase). CD39 is expressed by
a number of cell types, including endothelial cells and
leukocytes, and hydrolyzes the terminal phosphate of
ATP and ADP in an enzymatic cascade that generates
AMP (3–5). By depleting the potent prothrombotic and
proinflammatory signals of ADP and ATP, CD39 pre-
serves homeostasis in the vascular environment.
A growing body of literature describes the involve-
ment of CD39 and its apyrase activity in limiting
thrombosis and inflammation (6), yet relatively little is
known about the regulation of CD39, at either a
transcriptional or translational level. We recently dem-
onstrated that CD39 RNA and functional protein are
up-regulated potently by cAMP in murine macrophages
(7). To more fully understand how CD39 is regulated in
cells of the vascular wall, we explored the effects of
cAMP on CD39 in human endothelium. Our objective
was to reveal additional facets underlying control of
leukocyte-endothelial interaction in thrombosis and
inflammation.
The role of cAMP in modulating vascular tone has
been well established. In cardiac myocytes, increased
cAMP leads to increased contractility and tachycardia.
In vascular smooth muscle, cAMP acts as a vasodilator,
by activating cAMP-dependent PKA, which then phos-
phorylates myosin light chain kinase and reduces its
phosphorylation of myosin light chain, thereby inhibit-
ing contractile function of the actin/myosin complex
(8–10). cAMP also has a known important role in the
endothelium, where it preserves endothelial monolayer
barrier function (11).
To investigate the effect of cAMP in human endothe-
lial cells on CD39 expression, we employed a pharma-
cologic approach to modulate intracellular levels of
cAMP. Cilostazol has been administered as a safe and
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effective drug for the treatment of claudication in
peripheral arterial disease; it inhibits phosphodiester-
ase 3 (PDE3), an enzyme that depletes intracellular
cAMP by hydrolyzing its 3=-cyclic phosphate bond, by
competitively binding to the cAMP-specific binding site
of PDE3 (12, 13). Milrinone is used clinically in
patients with heart failure to improve contractility.
Milrinone was chosen as an independent tool to
confirm the effect of PDE3 inhibition on the expres-
sion of CD39 (14). The cell membrane-permeable
cAMP analog, 8-Bromo-cAMP (8-bromo-3=-5=-cyclic
adenosine monophosphate), was also used to increase intra-
cellular cAMP.
In this work, we show that increased intracellular
cAMP (through the specific inhibition of PDE3) leads
to the up-regulation of functional CD39 protein in
human endothelial cells as well as in murine macro-
phages. Most significantly, we found that macrophages
and endothelial cells regulate CD39 through separate
pathways, with the former utilizing transcriptional up-
regulation and the latter utilizing post-translational
regulation.
MATERIALS AND METHODS
Cell culture
All chemical reagents were obtained from Invitrogen (Grand
Island, NY, USA) unless specified. Human umbilical vein
endothelial cells (HUVECs) were isolated from human um-
bilical cords based on previously described methods (15).
Fresh cords were washed. The umbilical vein was attached to
a 10 ml syringe and flushed with isotonic saline buffer. The
cord was incubated with 2% collagenase 3 (Worthington
Biochemical, Lakewood, NJ, USA) in HBSS buffered with
HEPES at 37°C. Veins were then flushed with isotonic buffer,
and the flow through was centrifuged at 4°C, 190 g, 7 min.
Pellets were plated onto 35 mm plates coated with 0.2%
gelatin. Cells were not used beyond passage 4. Endothelial
basal medium (EBM-2) and endothelial growth medium
(EGM-2) supplement bullet kits (Lonza, Allendale, NJ, USA)
were reconstituted according to the manufacturer’s instruc-
tions. RAW cells (murine macrophage-like RAW 264.7 cells)
were obtained from ATCC (Manassas, VA, USA), and cul-
tured in RPMI 1640 medium supplemented with penicillin
(50 U/ml), streptomycin (5 g/ml), and 10% fetal bovine
serum (Invitrogen). Cells were treated with 8-Br-cAMP (Sigma, St.
Louis, MO, USA), PDE3 inhibitors (cilostazol or milrinone;
Sigma), or DMSO (Fisher, Pittsburgh, PA, USA) control for
indicated times in serum- and supplement-free EBM-2 me-
dium or serum-free RPMI 1640 medium.
Quantitative reverse transcription-PCR (qRT-PCR)
qRT-PCR was used to quantify RNA levels. HUVECs were
plated onto 0.2% gelatin-coated 6-well plates (Falcon). When
cells were confluent, they were serum-starved in EBM-2 and
then treated with a range of doses of cilostazol (30–100 M)
or DMSO (1 l/ml) (16, 17). After treatment, cells were
washed twice in PBS, and then total RNA was isolated using
RNeasy kits (Qiagen, Valencia, CA, USA). cDNA was made
using cDNA synthesis kits (Applied Biosystems, Grand Island,
NY, USA). Real-time qPCR was carried out using the 7000
detection system (Applied Biosystems) with 2 universal
mastermix and primers for human CD39 and human 2
microglobulin (Applied Biosystems). All data were normal-
ized to 2 microglobulin.
Whole-cell protein isolation
Following treatment with PDE3 inhibitors or DMSO as a
negative control, cells were washed twice with PBS (Invitro-
gen), scraped with a rubber policeman, and suspended in
ice-cold RIPA buffer supplemented with a tablet of a com-
plete mini protease inhibitor tablet (Roche, Branchburg, NJ,
USA). Cells were homogenized by 10 strokes through a sterile
30 gauge 1 ml insulin syringe. Lysed cells were centrifuged for
10 min at 13,000 g at 4°C, and the resulting supernatants were
transferred to new tubes. The samples were flash frozen in
aliquots and stored at 80°C. Concentrations were deter-
mined via a colorimetric protein assay (Bio-Rad, Hercules,
CA, USA).
Enzyme-linked immunosorbent assay (ELISA)
HUVECs were plated on 24-well plates (Corning, Tewksbury,
MA, USA) coated with 0.2% gelatin and grown until conflu-
ent. Cells were serum starved for 6 h before serum-free
treatment with 100, 250, 500, and 1000 M 8-Br-cAMP for 8 h.
Medium was transferred into microcentrifuge tubes (Eppen-
dorf, Hauppauge, NJ, USA), and samples were centrifuged
(500 g, 5 min, 4°C). Then 100 l of cell-free supernatants
were loaded onto 96-well plates (Nunc-Nalgene, Lafayette,
CO, USA) that had been coated overnight at 4°C with a rat
anti-CD39 antibodies (5 g/ml, MAB4398, R&D, Minneapo-
lis, MN, USA), and then blocked for 1 h at room temperature
with 4% BSA (Sigma) in PBS. Standard lanes were included
in each assay plate, with recombinant human CD39 (R&D)
in PBS. Wells were then washed 3 times with 0.05%
Tween-20 in PBS, and then probed with a sheep anti-CD39
antibody (5 g/ml, 2 h, room temperature, R&D AF4398).
Wells were washed 3 times again before probing with anti-
sheep biotinylated antibody for 1 h at room temperature.
This was followed by 3 more washes, and then avidin conju-
gated to alkaline phosphatase (1:800, 1 h, room temperature,
Sigma) was added. Wells were then washed 3 times, and 5 mg
of p-nitrophenyl phosphate, disodium salt in 5 ml of dietha-
nolamine buffer (Thermo Scientific, Pierce, Rockford, IL,
USA). Color was allowed to develop for up to 30 min, stopped
with 2 N NaOH, and then absorption measured at 405 nm by
a SpectraMax M5 microplate reader (Molecular Devices,
Sunnyvale, CA, USA).
LDH assay
Using a colorimetric LDH assay (Pierce Biotechnology, Rock-
ford, IL, USA), 15,000 cells were plated in triplicate in a
96-well format, and allowed to adhere overnight before
treatment with either vehicle control (Medium 199 (Gibco,
Grand Island, NY, USA)), or 8-Bromo-cAMP for 8 h. LDH was
then measured according to manufacturer instructions.
Briefly, cells were incubated in a reaction mixture containing
lactate, tetrazolium salt (2-(4-iodophenyl)-3-(4-nitrophenyl)-
5-phenyl-2H-tetrazolium) and diaphorase, and a red formazan
product was allowed to develop. Absorption was then mea-
sured at 490 and 680 nm using a SpectraMax M5 microplate
reader.
Immunoprecipitation
HUVECs were plated on 24-well plates (Corning) coated with
0.2% gelatin and grown until confluent. Cells were serum-
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starved for 6 h before serum-free treatment with 250 M
8-Br-cAMP for 18 h.
Cell supernatants were collected on ice and incubated with
gentle rocking overnight with protein-G agarose beads
(Roche), and then incubated with anti-human CD39 antibody
(Abcam, Cambridge, MA, USA) coated beads at 4°C. Beads
were washed, and purified CD39 protein was eluted and
quantified via standard Western blotting techniques.
cAMP measurement: competitive enzyme immunoassay
HUVECs were treated with cilostazol (100 M) or an equiv-
alent volume of DMSO, washed twice in PBS to wash away
traces of DMSO, and then intracellular cAMP levels were
measured according to manufacturer instructions of the
competitive enzyme immunoassay kit (Cayman, Ann Arbor,
MI, USA).
Immunofluorescence
HUVECs were plated on 4-well plastic chamber slides
(LabTek), with 0.2% gelatin coating. After cells had adhered
and grown to 40% confluence, cells were treated in serum-
free conditions with the following: Lonza EBM-2 basal me-
dium with DMSO as vehicle control, cilostazol (50, 100, 400
M), or milrinone (100, 200, 400 M). Cells were then fixed
for 15 min with ice-cold methanol, and then incubated
overnight with a mouse anti-CD39 antibody (1:100) at 4°C
followed by biotinylated horse anti-mouse IgG (1:100; Vector
Laboratories, Burlingame, CA, USA) for 1 h at room temper-
ature. An avidin-biotin-peroxidase complex was formed for 30
min at room temperature and then added to samples. Finally,
a tetramethylrhodamine-labeled tyramide was added (PerkinEl-
mer, Waltham, MA, USA). Nuclei were stained with DAPI.
Slides were mounted with Prolong Gold (Invitrogen) and
cured for 24 h. Slides were then imaged using a Nikon Eclipse
TE2000-E microscope (Nikon, Tokyo, Japan).
Radio-thin layer chromatographic (TLC) analysis of CD39
activities
TLC was used to assess CD39 enzymatic function. Total
protein of HUVECs was mixed with 1.0 mM [8-14C]ATP (MP
Biomedicals, Santa Ana, CA, USA) and 286 M AOPCP
(Sigma) in Medium 199 (Life Technologies) and incubated
at 37°C for 30 min. Reactions were stopped using 8M formic
acid, and the reaction mixture was then spotted onto silica gel
TLC plates (Fluka, Invitrogen). A ladder of [8-14C]ATP,
[8-14C]ADP, and [8-14C]AMP (MP Biomedicals) was used.
Nucleotides were separated by thin layer chromatography
with isobutyl alcohol, isoamyl alcohol, 2-ethoxyethanol, am-
monia, and water (9:6:18:9:15) (5). Separation was allowed to
occur for 5 h before plates were dried, exposed to a phos-
phorimaging screen (Eastman Kodak Co., Rochester, NY,
USA), and then analyzed using a Typhoon Trio Variable
Mode Imager (GE Healthcare, Livonia, MI, USA).
Western blotting assay
Total protein was quantified and added to 4 sample buffer
(Invitrogen), boiled for 3 min at 100°C, separated by 10%
SDS-PAGE, and electrophoretically transferred onto PVDF
membranes (Invitrogen). Membranes were probed with
mouse monocolonal IgG1 anti-CD39 antibodies (Abcam) and
HRP-conjugated anti-mouse antibodies (Sigma), and then
autoradiographed using enhanced chemiluminescence (ECL
detection system; Amersham Biosciences, Piscataway, NJ,
USA).
Statistics
Statistical analysis was performed using analysis of variance to
detect differences between groups. Groups were analyzed
with a one-way ANOVA, and further post hoc analysis using the
student Newman-Keuls method was applied (Prism). Differ-
ences were considered significant if P  0.05.
RESULTS
cAMP increases CD39 in the extracellular milieu
To analyze the potential role of cAMP in regulating
human endothelial CD39, we began by measuring
CD39 in HUVEC supernatants as a function of cAMP
levels (Fig. 1A). The cell-permeant cAMP analog 8-Bromo-
cAMP was used to achieve a gradation in cAMP levels.
ELISA data showed that CD39 protein increased with
the addition of cAMP, in what appeared to be a cAMP
dose-dependent manner. These supernatant samples
were measuring CD39 as released into the surrounding
Figure 1. (A) CD39 protein levels measured by ELISA:
Supernatants of HUVECs treated with either PBS (control) or
8-Br-cAMP were measured for CD39 via ELISA. Treatment
with this cell permeable analogue of cAMP increases extra-
cellular CD39. P0.001 between 1 mM vs. control and
P0.05 between 250 M and control. (A) LDH levels were
measured in HUVECs treated with either vehicle control or
8-Br-cAMP. cAMP treatment did not change levels of LDH
release.
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medium, thus indicating that intracellular cAMP levels
regulate CD39 levels. This suggested that either more
CD39 was being made or released, or less was being
eliminated. LDH levels were also measured (Fig. 1B), in
order to confirm that CD39 elevation after cAMP
treatment was not a result of cytotoxicity. Results
showed LDH levels in cAMP-treated samples were the
same across all conditions as LDH levels in control
samples.
PDE3 inhibition increases CD39 transcription
Having determined that extracellular CD39 elevated in
response to cAMP, we subsequently sought to establish
whether modulating intracellular cAMP would alter
membrane CD39 expression. Cilostazol was a primary
candidate to modulate cAMP because of its specific
PDE3 inhibitory activity (13) and for its safety profile in
humans. Treatment of RAW murine macrophages with
cilostazol resulted in increased CD39 mRNA as well as
protein as measured by qRT-PCR and Western blot,
respectively (Figs. 2 and 3). To confirm this finding as
a PDE3 class effect, RAW cells were also treated with
milrinone, and CD39 protein was measured. These
results were consistent with previous work, which
showed that murine peritoneal macrophage CD39 is
strongly up-regulated by treatment with 8-Bromo-cAMP
(7) and that a defined transcriptional pathway exists for
such regulation.
PDE3 inhibition increases CD39 protein expression
In human endothelial cells, there is no prior work
establishing a link between cAMP and CD39. Given the
significant role of endothelial cells in the maintenance
of vascular homeostasis, HUVECs were used to investi-
gate whether endothelium stimulated by cAMP can
result in the up-regulation of CD39. To confirm that
intracellular cAMP levels were indeed elevated after the
indicated treatment times using PDE3 inhibitors in
HUVECs, endogenous cAMP levels were measured with
or without cilostazol (Fig. 4). Results demonstrated that
cAMP levels were significantly elevated with cilostazol
treatments. Surprisingly, endothelial cells exhibited
markedly different responses to cAMP elevation, com-
pared with macrophages subjected to PDE3 inhibition.
There was no change in mRNA levels for CD39 (Fig. 5),
whereas CD39 protein levels measured by Western blot
elevated after treatment (Fig. 6), indicating that the
increase in CD39 protein was not at the transcriptional
level. Further evidence for the effect of PDE3 inhibition
on CD39 protein is shown in Fig. 7. HUVECs were
treated with a range of doses of either cilostazol or
milrinone and compared to control wells treated with
Figure 2. Effect of PDE3 inhibition on CD39 mRNA: RAW
macrophages were treated with 30 M cilostazol for 18 h and
then harvested for measurement of total mRNA by qRT-PCR.
P0.001 compared to control, n  4.
Figure 3. Effect of PDE3 inhibition on CD39 protein: RAW
macrophages were treated with DMSO (control), 30 M
cilostazol, or 50 M milrinone for 21 h, harvested for total
protein, and analyzed by Western blot. RAW macrophages
treated with cilostazol expressed 44% more CD39 compared
to DMSO-treated controls (P0.05, n3). Macrophages
treated with milrinone had a 74% increase in CD39 com-
pared to DMSO (P0.05, n3).
Figure 4. Quantification of intracellular cAMP level: HUVECs
treated with 100 M cilostazol show 2.97-fold increase in
cAMP levels (P0.05, n7). Analysis of intracellular cAMP
performed via competitive binding assay.
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DMSO as a vehicle control. Results from Western blots
of whole cell lysates indicate a marked rise in CD39
protein levels as a function of cilostazol or milrinone
dose. CD39 elevation peaks between 200 and 400 M.
Higher doses of milrinone were used in order to
account for the relatively short half-life of milrinone
compared to cilostazol, which has been cited as 2.3
and 11 h, respectively (18, 19).
Immunofluorescent imaging of HUVECs treated
with milrinone or cilostazol and then surface stained
for CD39 with tetramethylrhodamine (Figs. 8 and 9)
further confirmed that CD39 protein is elevated after
treatment. This also demonstrated that CD39 expres-
sion is increased after PDE3 inhibition on the plasma
membrane, where it has been shown to be active (20).
Since CD39 mRNA was not affected by treatment, we
considered the possibility that regulation of CD39 in
HUVECs may occur via post-translational modifica-
tions, possibly involving changes in the intracellular
trafficking or release of CD39. Post-translational con-
trol was supported by an immunoprecipitation assay
probing for ubiquitinated CD39 (Fig. 10). Here HUVECs
were treated with either control DMSO or 8-Br-cAMP,
followed by precipitation with beads coated with anti-
human CD39 antibody. Using Western blot, samples
were sequentially evaluated for ubiquitin and CD39
expression. The ratio of ubiquitin expression to CD39
expression was diminished after treatment with 8-Br-
cAMP (by 43%, n3, P0.05). The data indicated that
cAMP is likely raising CD39 levels by preventing CD39
ubiquitination in HUVECs.
Effect of PDE3 inhibition on CD39 activity
To assess whether increases in CD39 protein, as mea-
sured by Western blots of cell lysates, resulted in
changes in ATPase and ADPase activity, an activity assay
measuring the breakdown of radioactively labeled ATP
was performed. Nucleotides were separated by TLC
(Fig. 11). Signal density indicates the relative levels of
nucleotides present in samples at the time of measure-
ment and thus serves as a measure of CD39 activity.
Peaks 1, 2, and 3 correspond to ADP measured in
HUVEC samples treated with DMSO (control), cilosta-
zol, or milrinone, respectively. Both cilostazol and
milrinone increased CD39 activity significantly com-
pared with control DMSO-treated HUVECs. As a con-
firmatory test of relative differences in CD39 activity
after PDE3 inhibitor treatment, a malachite green assay
was performed on HUVECs treated with varying doses
of cilostazol or milrinone (Fig. 12A, B). Here the
presence of inorganic phosphates generated by the
cleavage of ATP and ADP was measured, where higher
concentrations of inorganic phosphate indicate greater
apyrase activity. These measurements indicate that both
ATP- and ADPase activity are elevated in cilostazol and
milrinone-treated samples, thus confirming the results
of the TLC assay.
DISCUSSION
CD39, a widely expressed plasmalemmal nucleotidase,
occupies a unique niche in the vascular milieu, with a
dichotomous role depending on physiological or dis-
eased conditions. Under normal conditions in the
absence of stressors such as hypoxia/ischemia, high
shear stress, and triggers for inflammation (cytokines/
chemokines), CD39 helps to maintain a homeostatic
environment (21–23), maintaining blood fluidity and
inhibiting inflammation. In the presence of these inju-
rious conditions, however, one of the most potent
signals for platelet aggregation, ADP, as well as proin-
flammatory signals such as ATP, are released into the
Figure 6. CD39 protein expression by Western blot: CD39
expression in HUVECs increased after 18 h of treatment with
50 M of cilostazol or 200 M of milrinone (2- and 2.5-fold,
respectively) compared to DMSO control (P0.05 and
P0.01, n3).
Figure 5. CD39 mRNA levels by qRT-PCR: HUVECs treated
with 30 or 100 M cilostazol showed no difference in CD39
mRNA expression compared to control (n3).
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extracellular environment. When this occurs, the extra-
cellular concentration of ADP and ATP increases mark-
edly. Low levels of ATP act as communication between
cells that no injuries are present (24), and most recep-
tors that bind ATP belonging to the class of P2X
receptors are maximally activated at these low concen-
trations. However, the P2X7 receptor is activated only
at the high levels of ATP (	100 M) (25, 26) that
signal danger and therefore is the main ATP-driven
signaling pathway of injury. The activation of this
pathway leads to increased 
m2 integrins and in-
creased leukocyte recruitment. In short, the presence
of high local concentrations of ATP serves as an acute
sign of danger and triggers greater inflammation. CD39
acts to dissipate both ADP and ATP, limiting thrombo-
sis, coagulation, and inflammation (23). Though this
role of CD39 has largely been determined, many ques-
tions surrounding the regulation of CD39 on both
transcriptional and post-translational levels remain un-
answered.
Pleiotropy of PDE inhibition
Endothelial cells have been described to express several
of the 11 phosphodiesterase family members, including
PDE2, PDE4, PDE3, and PDE5 (27), and the last 3 of
these have been targeted for a diverse range of clinical
uses. For example, roflumilast and cilomilast are PDE4
inhibitors developed for the treatment of chronic ob-
structive pulmonary disease, and other drugs targeting
PDE4 inhibition have been researched as antidepres-
sants and have been shown to improve memory in a
rodent model (28, 29). PDE5 inhibitors are best known
for their role in facilitating vascular smooth muscle
Figure 7. Effect of PDE3 inhibition on CD39 is dose dependent: HUVECs were treated with varying concentrations of cilostazol
(50–400 M) or milrinone (100–400 M). After 18 h of treatment, cells were washed and collected for analysis via Western blot.
The results show that CD39 increases in a dose-dependent manner (n3, P0.05 for cilostazol for control vs. 400 M and
P0.01 for milrinone control vs. 200 M).
Figure 8. Effect of PDE3 inhibition on CD39 protein visualized by immunofluorescence microscopy: HUVECs were treated for
18 h with control DMSO or milrinone (100–400 M). Cells were then fixed in methanol and labeled CD39 with
tetramethylrhodamine and nuclei with DAPI before imaging using a20 objective. A) DMSO (control); (B) 100 M milrinone;
(C) 200 M milrinone; (D) 400 M milrinone.
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relaxation, and drugs such as sildenafil and tadalafil
have been developed for the treatment of erectile
dysfunction and for treatment of pulmonary arterial
hypertension (28, 30). PDE3 inhibitors have also been
a target of interest, particularly useful as vasodilators in
the treatment of heart failure, and two of these were
specifically used herein as a tool to modulate intracel-
lular cAMP levels. PDE3 is particularly interesting in
relation to its potential effects on CD39, as it is impor-
tant for regulating platelet aggregation by affecting
intracellular cAMP levels. It is to this class that cilostazol
and milrinone belong, the former developed as a
vasodilator and platelet inhibitor and the latter as a
regulator of cardiac contractility and vasodilator in the
treatment of heart failure.
Effects of PDE3 inhibition
Cilostazol has been used in the treatment of intermit-
tent claudication in the context of peripheral arterial
disease (31). It is an antithrombotic that acts as an
arterial vasodilator (32) and has been shown to prevent
platelet aggregation stimulated by collagen, ADP, epi-
nephrine, thrombin, arachidonic acid, and shear stress
(31, 33). While the mechanism of action of cilostazol
has yet to be fully elucidated, it is known that cilostazol
acts as a specific inhibitor of PDE3. This inhibition of
Figure 9. Effect of PDE3 inhibition on CD39 protein visualized by immunofluorescence microscopy: HUVECs were treated for
18 h with control DMSO or cilostazol (50–400 M). Cells were then fixed in methanol and labeled CD39 with tetramethyl-
rhodamine and nuclei with DAPI before imaging using a 20 objective. A) DMSO (control); (B) 50 M cilostazol; (C) 100 M
cilostazol; (D) 400 M cilostazol.
Figure 10. Effect of PDE3 inhibition on ubiquitination of
CD39: HUVECs were treated for 18 h with 8-Br-cAMP or
control PBS. Cells were then washed in PBS, harvested, and
incubated with beads coated with anti-human CD39 antibody.
Beads were then washed and the protein eluted and analyzed
via Western blot. Membranes were first probed with anti-
ubiquitin (UBI) antibody, then stripped and reprobed with
anti-human CD39 antibody (n3, P0.05). Treatment with
8-Br-cAMP resulted in 43% less ubiquitin bound to CD39.
Figure 11 Functional assessment of CD39 activity following
PDE3 using radio-thin-layer chromatography (TLC): Total
cell lysates of HUVECs treated with either DMSO, cilostazol
(50 M), or milrinone (200 M) were incubated with 14C-
labeled ATP. Total ADP was measured and normalized to
total protein and total radiation per lane (n5, *P0.05,
**P0.01). Peak 1 indicates ADP measured in DMSO (con-
trol) treated samples, peak 2 indicates ADP measured in
cilostazol-treated samples, and peak 3 indicates ADP mea-
sured in milrinone-treated samples.
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PDE3 leads to an increase in intracellular cAMP levels,
which then potentiates other signaling pathways driven
by cAMP, and finally results in vasodilation and sup-
pression of platelet aggregation (34). It is different
from other drugs of its class such as milrinone, in that
cilostazol may also exert beneficial effects on the endo-
thelium by reducing adenosine reuptake into endothe-
lial cells, platelets, erythrocytes, and myocytes, thereby
increasing extracellular adenosine signaling through
A1 and A2 receptors (35, 36). Milrinone, in contrast to
cilostazol, has been used in the treatment of patients
with heart failure (37). Though its half-life is consider-
ably shorter than that of cilostazol, it has been shown to
have a greater stimulatory effect on cAMP in ventricular
myocytes compared to cilostazol, and to have a greater
effect on contractility in hearts (17). Both drugs have
been demonstrated to act specifically on PDE3 and
increase intracellular cAMP and are used herein to
demonstrate that specific PDE3 inhibition, as opposed
to drug-specific effects, is responsible for changes to
CD39 expression.
Transcriptional regulation of human CD39
Very little is currently known about the transcriptional
mechanisms responsible for the expression of CD39.
However, it has recently been established that CD39
mRNA and protein can be increased in murine RAW
macrophages and murine peritoneal macrophages af-
ter exposing cells to 8-Br-cAMP (7). There are several
cAMP response elements (38) in the murine CD39
promoter region, of which one is proximal to the
transcriptional start site to regulate CD39 directly. The
human CD39 promoter region, in contrast, has a
handful of AP-1/cre-like sequences encoded distal to
the start site, indicating that cAMP-driven effects in
endothelial cells may indeed be different from the
direct transcriptional pathway in murine macrophages.
This is particularly evident here, where inhibition of
PDE3 led to significant increases in protein expression
and activity of endothelial CD39, but led to no differ-
ences in mRNA levels (Figs. 5–9, 11, and 12). This is in
contrast to RAW macrophages, which showed increases
in both CD39 protein and mRNA (Figs. 2 and 3).
Differential regulation of CD39 in endothelial cells:
ubiquitination
The fact that CD39 can be detected in higher levels
after an increase in intracellular cAMP despite rela-
tively unaltered mRNA levels indicates that changes
may be occurring on a post-translational level. How-
ever, extremely little is known about the degradation
and turnover of CD39. Here we raise the possibility that
CD39 may be ubiquitinated. Several lines of evidence
led us to propose this as a possibility. First, the literature
suggests that PDE inhibition and the subsequent mod-
ulation of intracellular cAMP can inhibit ubiquitination
(39). In this case, PDE4 inhibition led to the inhibition
of ubiquitin-driven protein degradation in rat skeletal
muscles. This activity seems to be dependent in part on
an increase in intracellular cAMP, in that cAMP levels
induced by a 2-agonist led to the suppression of two
ubiquitin ligases (40). Taken together with data pre-
sented here showing that cAMP treatment leads to
significantly less ubiquitinated CD39, it may be indica-
tive of an endothelial mechanism by which CD39
expression is modulated posttranslationally. A second
indication that CD39 may be regulated by ubiquitina-
tion is that CD39 protein contains a Ran binding
protein M (RanBPM or RanBP9) binding site on its N
terminus (41). RanBPM is a widely expressed scaffold-
ing protein that mediates interactions between the
cytoplasmic domains of proteins and other signaling
moieties, and its various associated activities range from
promoting apoptosis (42) to microtubule reorganiza-
tion (43). Relevant to this study, others have shown that
protein binding to RanBPM can inhibit ubiquitination
(44, 45). These data suggest that CD39 association with
Figure 12. Measurement of inorganic phosphate generation
following PDE3 inhibition using a malachite green assay:
HUVECs were treated with either DMSO, along with varying
doses of either cilostazol (50–400 M) or milrinone (100–
400 M). A) inorganic phosphate levels after the addition of
ADP, thus indicating relative ADPase activity. B) inorganic
phosphate levels after the addition of ATP, thus indicating
relative levels of combined ATPase and ADPase activity (n6,
*P0.05, **P0.01, ***P0.001).
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RanBPM may play a role in how CD39 expression is
regulated.
In conclusion, we have shown that while the inhibi-
tion of PDE3 results in an increase in CD39 expression
in both macrophages and endothelial cells, the mech-
anisms governing this up-regulation differs between the
two. In macrophages, there is a strong basis for the
direct involvement of cAMP in the transcriptional reg-
ulation of CD39. In contrast, endothelial cells are only
affected at the protein level, and we have shown here
that PDE3 inhibition results in differential ubiquitina-
tion, with elevation of CD39 protein levels. While
further study into this mechanism is ongoing, the
demonstration of CD39 modulation by PDE3 inhibition
is unique. That this was achieved through the utiliza-
tion of available therapeutics, cilostazol and milrinone,
presents the potential of repurposing currently used
PDE3 inhibitors for the targeted control of CD39 and
extracellular nucleotide signaling.
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